Literature DB >> 15203748

Laboratory tests for the antiphospholipid syndrome: current concepts.

Freda Passam1, Steven Krilis.   

Abstract

There is increased scientific interest in the diagnosis of the antiphospholipid syndrome (APS), as therapeutic interventions can lead to substantial improvement in clinical outcome. As the clinical features of APS are far from specific, a sound laboratory method is needed to support or exclude the diagnosis. Two methods are currently used for the diagnosis of APS: (1). ELISA-based immunoassays for the detection of anticardiolipin (aCL) antibodies; and (2). clotting assays for determination of the lupus anticoagulant (LA). However, the first method is limited by a low specificity, and the second by low sensitivity. Furthermore, for both methods standardisation is unsatisfactory. Therefore, a number of new assays have been proposed as alternative or supplementary to aCL and LA tests. These include the anti-beta-2-glycoprotein I or antiprothrombin ELISAs, an ELISA utilising a phospholipid mixture, clotting assays with varying activators and assays utilising chromogenic substrates. This review presents a brief outline of APS, the autoantibodies associated with this syndrome, the basic principles of the standard assays used and a description of newer methods currently being validated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15203748     DOI: 10.1080/00313020410001671966

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  9 in total

1.  Autoimmune hemolytic anemia in systemic lupus erythematosus: association with thrombocytopenia.

Authors:  Diogo Souza Domiciano; Samuel Katsuyuki Shinjo
Journal:  Clin Rheumatol       Date:  2010-05-15       Impact factor: 2.980

Review 2.  The role of antiphospholipid antibodies (aPls) in infertile women: the long-lasting experience.

Authors:  Zdenka Ulcova-Gallova
Journal:  Reprod Med Biol       Date:  2014-10-07

3.  Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity.

Authors:  R Rolla; M Vidali; R Serino; P Pergolini; E Albano; G Bellomo
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

4.  Anticardiolipin antibodies in proliferative diabetic retinopathy: An additional risk factor.

Authors:  Maha Shahin; Amany M El-Diasty; Mohamed Mabed
Journal:  Saudi J Ophthalmol       Date:  2009-08-05

5.  Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases.

Authors:  Wei-Shiang Lin; Pei-Chih Chen; Cheng-De Yang; EunJung Cho; Bevra H Hahn; Jennifer Grossman; Kwan-Ki Hwang; Pojen P Chen
Journal:  Arthritis Rheum       Date:  2007-05

Review 6.  "New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome.

Authors:  Roberta Misasi; Antonella Capozzi; Agostina Longo; Serena Recalchi; Emanuela Lococo; Cristiano Alessandri; Fabrizio Conti; Guido Valesini; Maurizio Sorice
Journal:  J Immunol Res       Date:  2015-03-19       Impact factor: 4.818

7.  Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome.

Authors:  Fatima El-Assaad; Steven A Krilis; Bill Giannakopoulos
Journal:  Thromb J       Date:  2016-10-04

8.  Autoimmune Factor V Deficiency That Took 16 Years to Diagnose due to Pseudodeficiency of Multiple Coagulation Factors.

Authors:  Takaaki Kato; Takaya Hanawa; Mea Asou; Tomohiko Asakawa; Hisashi Sakamaki; Makoto Araki
Journal:  Case Rep Med       Date:  2021-01-12

9.  Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients?

Authors:  R Kreidy; N Irani-Hakime
Journal:  Vasc Health Risk Manag       Date:  2009-08-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.